Healthcare Revenue Cycle Management Software Market to grow by USD 54.95 Billion from 2025 to 2029, Driven by need to reduce revenue leakage, AI impact
Healthcare Revenue Cycle Management (RCM) Software Market 2025-2029: Scope
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The healthcare revenue cycle management (rcm) software market report covers the following areas:
Healthcare Revenue Cycle Management (RCM) Software Market Size
Healthcare Revenue Cycle Management (RCM) Software Market Trends
Healthcare Revenue Cycle Management (RCM) Software Market Industry Analysis
Porter's Five Forces Analysis
Customer Landscape
The healthcare revenue cycle management (rcm) software market is fragmented, and the degree of fragmentation will accelerate. The growing need for reducing revenue leakage in healthcare system will offer immense growth opportunities. However, the Interoperability issues associated with healthcare RCM software will hamper the market growth
Healthcare Revenue Cycle Management (RCM) Software Market 2025-2029: Drivers & Challenges
The Healthcare Revenue Cycle Management (RCM) software market is witnessing significant growth due to the increasing need for efficient billing and payment management applications in clinics and laboratories. Key stakeholders, including healthcare providers and patients, seek real-time insights into workflows for data accuracy. RCM solutions are essential for managing claims, ensuring interoperability, and data integration of electronic data from petabytes to terabytes of unstructured and structured data. Epic Systems and CareCloud Corporation lead the market, offering licensing, implementation, IT support, and maintenance services. Buying behavior is influenced by factors like data verification, validation, and custom interfaces. Emerging countries and healthcare facilities in America are adopting RCM software to digitize their legacy systems using HCIT tools. Artificial intelligence, machine learning, algorithms, and predictive analytics are driving innovation in RCM, enhancing drug discovery and improving patient volumes.
The Healthcare Revenue Cycle Management (RCM) software market is experiencing significant growth due to the increasing complexity of the healthcare industry. Challenges include virtual assistance for patient engagement, managing medical images, and ensuring patient access and collections. Denials and patterns require specialized expertise, while Electronic Health Records (EHRs) and healthcare integration demand advanced technology. Health information exchanges and data security are crucial concerns in the healthcare market, with ransomware attacks and data breaches a growing threat. Compliance with regulatory landscapes and financial performance optimization are key areas of focus for healthcare payers and providers. Manufacturing companies and outsourcing services offer product development and optimization, while human resources and contract research/development provide valuable services. Financial outcomes are a top priority, requiring in-house research and facilities to stay competitive in the ecosystem market.
To learn more about the global trends impacting the future of market research, download a PDF sample
Segment Overview
This healthcare revenue cycle management (rcm) software market report extensively covers market segmentation by
Deployment
End-user
Geography
1.1 Cloud-based- The healthcare revenue cycle management (RCM) software market is witnessing significant growth, particularly in the cloud-based deployment segment. This trend is driven by the benefits of quick deployment, improved flexibility and scalability, real-time data visibility, and customization capabilities. Cloud-based RCM solutions enable seamless integration with other healthcare software solutions, such as online booking and payment systems. Flexible payment options, including monthly subscriptions and pay-as-you-go models, make these solutions cost-effective for various-sized healthcare organizations. Small and medium-scale healthcare providers are increasingly adopting cloud-based RCM software due to its scalability and cost savings. Large-scale healthcare enterprises, with their vast data volumes, can optimize costs by storing critical data on-premises and infrequently used data on public cloud servers. Innovations in data security will further boost the adoption of cloud-based RCM solutions among large enterprises during the forecast period. In summary, the cloud-based deployment segment is expected to grow at a faster rate than the on-premises deployment segment due to its numerous advantages.
To learn more, request a FREE sample
Healthcare Revenue Cycle Management (RCM) Software Market 2025-2029: Key Highlights
CAGR of the market during the forecast period 2025-2029
Detailed information on factors that will assist healthcare revenue cycle management (rcm) software market growth during the next five years
Estimation of the healthcare revenue cycle management (rcm) software market size and its contribution to the parent market
Predictions on upcoming trends and changes in consumer behavior
The growth of the healthcare revenue cycle management (rcm) software market across North America, Europe, APAC, South America, and Middle East and Africa
Analysis of the market's competitive landscape and detailed information on vendors
Comprehensive details of factors that will challenge the growth of healthcare revenue cycle management (rcm) software market vendors
Healthcare Revenue Cycle Management (RCM) Software Market Scope
Report Coverage
Details
Base year
2024
Historic period
2017-2021
Forecast period
2025-2029
Growth momentum & CAGR
Accelerate at a CAGR of 13.7%
Market growth 2025-2029
USD 54953.5 million
Market structure
Fragmented
YoY growth 2022-2023 (%)
11.5
Regional analysis
North America, Europe, APAC, South America, and Middle East and Africa
Performing market contribution
North America at 65%
Key countries
US, Canada, Germany, UK, France, Japan, India, China, Australia, and Brazil
Competitive landscape
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled
3M Co., ALLSCRIPTS HEALTHCARE SOLUTIONS INC., athenahealth Inc., Change Healthcare Inc., Chetu Inc., Cognizant Technology Solutions Corp., CompuGroup Medical SE and Co. KGaA, Computer Programs and Systems Inc., Epic Systems Corp., Experian Plc, International Business Machines Corp., OSP, Providence Health and Services, Quest Diagnostics Inc., QWay Healthcare Inc., R1 RCM Inc., The SSI Group LLC, Waystar Inc., WellSky Corp., and ZH Healthcare Inc.
Market dynamics
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
About USTechnavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
ContactTechnavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.comWebsite: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/healthcare-revenue-cycle-management-software-market-to-grow-by-usd-54-95-billion-from-2025-to-2029--driven-by-need-to-reduce-revenue-leakage-ai-impact--technavio-302376648.html
SOURCE Technavio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hypebeast
4 hours ago
- Hypebeast
HOKA Adds the Mafate Speed 4 Lite and Project Transport to Its Stealth/Tech Collection
Product Names:HOKA Stealth/Tech Mafate Speed 4 Lite & Project TransportColorways:White/Black, Black/White, and Black/WhiteSKUs:1168971 and 1168953Retail Price:$160 USD to $180 USDRelease Date:July 1Retailers:HOKA HOKAwas named the best footwear brand in theHypebeast100 Awards, in part thanks to the introduction of theMafate Speed 4 LitewithSatisfy. It has since brought the model to the masses via an in-line launch. Another bold step forward for the sportswear brand came at the start of the 2025, when HOKA presented the zipper shroud-equippedProject Transport. Now, both models have come together for the latest addition to HOKA's utilitarian Stealth/Tech collection. Looking first at the Mafate Speed 4 Lite, colorways of 'White/Black' and 'Black/White' offer a translucent ripstop upper, reflectivity, a haptic dot matrix print, and Profly midsole. From there, the Project Transport dons a 'Black/White' finish that sees ripstop applied to its signature zipper shroud, a 3D-printed grid upper, and similar detailing with reflectivity and a haptic dot matrix print. All three sneakers are also backed by an exploration-ready outsole from Vibram. For those looking to pick up a pair from this latest expansion of HOKA's Stealth/Tech collection, all three shoes are available now via the brand. Pricing starts at $160 USD for the Project Transport and goes up to $180 USD for the Mafate Speed 4 Lite.
Yahoo
6 hours ago
- Yahoo
Standard Chartered Predicts Bitcoin Will Hit $135K by Q3 End, $200K by Year-End
Standard Chartered expects bitcoin (BTC-USD) to continue its 2025 rally, forecasting a climb to $135,000 by the end of Q3 and $200,000 by year-end. The bank's revised target reflects what it calls unusually strong inflows into spot bitcoin ETFs and corporate treasuries. Warning! GuruFocus has detected 6 Warning Sign with META. Bitcoin hit an all-time high of $112,000 in Q2below the bank's earlier $120,000 forecast but still well above levels seen earlier this year. According to the report, U.S.-listed spot ETFs brought in $12.4 billion last quarter, representing 120,000 BTC. Meanwhile, treasury buyers added another 125,000 BTC to their reserves. Geoff Kendrick, head of digital assets research at Standard Chartered, said the combined 245,000 BTC bought in Q2 could be surpassed in Q3. He pointed to continued strength in ETF inflows, which now total nearly $49 billion since launch in January 2024. ETF demand for bitcoin is outpacing traditional hedges. Bitcoin ETF inflows in Q2 exceeded the $6.9 billion that flowed into gold ETFsa sign, Kendrick said, of investor rotation rather than geopolitical hedging. Regulatory developments could offer another boost. Standard Chartered flagged two potential catalysts: passage of a U.S. stablecoin bill and a possible announcement from President Trump replacing Fed Chair Jerome Powell before October. Kendrick believes these driversplus the ETF momentumcould send bitcoin to fresh highs. While halving cycles in the past have triggered post-peak corrections, he says strong institutional buying this time may mute any downside. This article first appeared on GuruFocus.
Yahoo
8 hours ago
- Yahoo
First Lung Organoid with Organ-Specific Blood Vessels
Advanced lab-grown tissues help show how special lung cells develop, shedding light on rare ACDMPV disease and suggesting potential ways to repair damage from viral infections such as COVID-19 CINCINNATI, June 30, 2025 /PRNewswire/ -- A team of experts at Cincinnati Children's reports another powerful step forward in organoid medicine: success at making human lung tissue that can produce its own blood vessels. Their findings, published in the same month as a similar success involving liver organoids, reflect a new wave of advanced lab-grown tissues that can be used immediately in many research applications while moving ever closer to serving as living tissues that can directly repair damaged organs. Details were posted online June 30, 2025, in the journal Cell. "Prior to our study, the development of lung organoids with organotypic vasculature had not been achieved," says co-corresponding author Mingxia Gu, MD, PhD. "Notably, this method also could be applied to other organ systems such as intestine and colon." Gu, now at UCLA, was a member of the Center for Stem Cell and Organoid Medicine (CuSTOM) and Division of Pulmonary Biology at Cincinnati Children's while this research was conducted. Co-first and co-corresponding author Yifei Miao, PhD, (now at the Chinese Academy of Sciences, Beijing) also was with Cincinnati Children's for this work. Co-corresponding author Minzhe Guo, PhD, remains with Cincinnati Children's along with several co-authors involved in this study. Overcoming a major challenge Researchers have been working for years to grow organoids -- sometimes called "organs in a dish." Creating organoids involves converting mature human cells (such as blood or tissue cells) back into fetal-like stem cells that can be coaxed into growing a wide range of other tissue types. Unlike disconnected human cells kept alive in a dish, these are growing, developing mini-organs that form into seed-sized spheres that mimic the unique functions of full-sized organs. Intestines that absorb and secrete. Stomachs that produce digestive acids. Hearts that pulse. Brain tissues with firing nerve cells and so on. Cincinnati Children's has been a leader in organoid development since 2010 when experts here produced the world's first functional intestinal organoid grown from induced pluripotent stem cells (iPSCs). More recently, the challenge has been learning how to grow organoid tissues that can connect with the rest of the body to integrate nerve connections, blood vessels, bile ducts, immune systems and more. During pregnancy, these differing tissue types naturally find each other as the fetus matures and becomes more complex. Organoid developers seek to re-produce these steps in the laboratory, which eventually may allow people to receive custom-grown tissues that could patch damage or boost disrupted functions. Simpler forms of organoids have already begun transforming medical research, allowing many scientists to use living human tissue models to study disease while reducing current reliance on animal models to develop new medicines. But without the ability to make internal blood vessels, the tiny seeds lack the ability to grow into larger, more useful tissues. How the team solved the vascular riddle The new study thoroughly recounts the results of many experiments the team conducted to demonstrate success at inducing blood vessel formation. The work spanned four years and involved more than 20 people at Cincinnati Children's plus collaborations with experts at several other organizations. "The challenge in vascularizing endodermal organs, particularly the lung, stems from different signaling requirements for lung epithelial versus vascular differentiation," says Miao. "Our success in this endeavor is attributable to our unique differentiation method." In essence, the team grew iPSCs from multiple cell types then found the right moment to introduce them to each other. The resulting cell signals helped flip a developmental switch so that progenitor cells that could have become either blood vessels or the outer walls of the lung wound up becoming blood vessels. In achieving this vital step, the team: Produced lung organoids that include respiratory bronchial epithelial cells (RAS cells), a human cell type not previously reported in conventional lung organoid models. Pinned down the developmental moments when a rudimentary gut tube begins to send some cells to form the lungs while sending other cells to form the stomach and intestine. While the basic steps of this transformation have been studied in animals, it had not been possible to study this stage of development in humans without killing fetuses. Demonstrated that the rare disease ACDMPV occurs when cell signaling "crosstalk" gets disrupted during this early blood vessel formation stage. Within days of birth, infants born with Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV) struggle to breathe because their lungs' air sacs (alveoli) and blood vessels are malformed. Nearly all infants with this condition die within the first month of life, according to the National Organization for Rare Disorders. Revealed key functional information about the cells involved in gas exchange inside the human lung. Their learnings help explain the damage within tiny blood capillaries that occurs in the lungs in response to injuries. These new clues offer fresh ideas for developing ways to protect and potentially restore affected lung tissues. What's Next? Cincinnati Children's has filed patent applications related to the methods developed here to produce organoids with blood vessel formation capabilities and the CuSTOM team is moving to further develop this technology. "We look forward to continuing to learn more about the fundamental biology involved in organ formation and applying those discoveries to improving outcomes across a wide range of difficult human diseases and conditions," says Aaron Zorn, PhD, co-director of CuSTOM and director of the Division of Developmental Biology. In addition to publishing these findings in Cell, co-authors plan to present their work at the Keystone conference in Kyoto, Japan (iPSCs: Progress, Opportunities, and Challenges) in January 2026. About the study Cincinnati Children's co-equal first authors were Miao, Nicole Pek, BS, and Cheng Tan, MD. Contributing co-authors from Cincinnati Children's were Cheng Jiang, MS, Zhiyun Yu, PhD, Kentaro Iwasawa, MD, PhD, Min Shi, MD, PhD, Daniel Kechele, PhD, Nambirajan Sundaram, PhD, Victor Pastrana-Gomez, MSTP student, Debora Sinner, PhD, Cheng-Lun Na, PhD, Keishi Kishimoto, PhD, Jason Tchieu, PhD, Jeffrey Whitsett, MD, Kyle McCracken, MD, PhD, Michael Helmrath, MD, James Wells, PhD, Takanori Takebe, MD, PhD, and Aaron Zorn, PhD. Contributing co-authors included experts from Harvard Medical School, Icahn School of Medicine at Mount Sinai, Sophia Children's Hospital (The Netherlands), Boston University This research also was supported by the Discover Together Biobank, the Bio-Imaging and Analysis Facility, and the Integrated Pathology Research Core at Cincinnati Children's and the University of Cincinnati Proteomics Laboratory. Funding sources for this work included: the National Institutes of Health (R01HL166283, DK128799-01, N01-75N92020C00005 and R01HL095993); an Endowed Scholar Award from the Cincinnati Children's Research Foundation; the American Heart Association (1013861 and 906513); the Falk Transformational Awards Program; and the Brigham Research Institute. Learn more about working with CuSTOM Learn how donors can support ongoing organoid research at Cincinnati Children's View original content to download multimedia: SOURCE Cincinnati Children's Hospital Medical Center Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
